AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability
Development services for gene and cell therapies is planned to begin first in 2025
Development services for gene and cell therapies is planned to begin first in 2025
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
ABDM Microsites Mobile Application for field officers and ABDM Microsites Dashboard launched for effective on-ground implementation and monitoring
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
The launch of R3SET Detox Candies positions the brand at the forefront of the wellness journey
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Lacosamide is indicated to treat partial-onset seizures
10+ emerging markets, Japan & ANZ transition in final phase
Subscribe To Our Newsletter & Stay Updated